Hours

Minutes

Seconds

-40%

on all subscriptions*

Exceptional extension!

Enjoy this offer

* See conditions under "Our services"

Valuation: Guizhou Yibai Pharmaceutical Co., Ltd.

Market Cap	2.56B 378M 332M 306M 286M 536M 35.79B 545M 3.67B 1.42B 17.56B 1.42B 1.39B 61.03B	P/E 2024	-8.86x	P/E 2025	-9.48x
Enterprise Value	2.78B 410M 360M 332M 311M 582M 38.82B 592M 3.98B 1.54B 19.05B 1.54B 1.51B 66.2B	EV / Sales 2024	1.48x	EV / Sales 2025	1.79x
Free-Float	67.99%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Chart: Guizhou Yibai Pharmaceutical Co., Ltd.

Timeframe

Style

Dynamic Chart

Latest news : Guizhou Yibai Pharmaceutical Co., Ltd.

04-23	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
30/10/25	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
18/09/25	Authorities Lift Suspension Order on Yibai Pharma's Production, Sales of Children's Cough Syrup	MT
20/08/25	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
06/08/25	Yibai Pharmaceutical Gets Order to Suspend Marketing of Children's Cough Syrup	MT
25/04/25	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
28/11/24	Guizhou Yibai Pharmaceutical Co., Ltd. 's Equity Buyback announced on November 29, 2023 has expired.	CI
25/10/24	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
10/10/24	Tranche Update on Guizhou Yibai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 30, 2023.	CI
09/09/24	Guizhou Yibai Pharmaceutical CFO Steps Down; Successor Named	MT
04/09/24	Guizhou Yibai Pharmaceutical Gets China Approval for Multiple, Non-Hodgkin's Lymphoma Drug	MT
23/08/24	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
03/07/24	Tranche Update on Guizhou Yibai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 30, 2023.	CI

More news

Managers and Directors: Guizhou Yibai Pharmaceutical Co., Ltd.

Manager	Title	Age	Since
Ya Qi Dou CEO	Chief Executive Officer	42	13/05/2021
Xianti Zeng DFI	Director of Finance/CFO	52	06/09/2024
Zhi Wei Wang PRN	Corporate Officer/Principal	56	17/09/2019

Director	Title	Age	Since
Qi Ling Dou CHM	Chairman	66	22/01/2009
Zhi Wei Wang BRD	Director/Board Member	56	21/02/2011
Ya Qi Dou BRD	Director/Board Member	42	03/01/2019

More insiders

Guizhou Yibai Pharmaceutical Co Ltd is a China-based company principally engaged in pharmaceutical industry, medical services, and big health industry businesses. The pharmaceutical industry business is mainly engaged in the research and development, production and sales of chemical drugs, traditional Chinese medicines, biological drugs and other drugs. The medical service business is mainly engaged in the operation and management of comprehensive hospitals, tumor specialty hospitals, and tumor radiotherapy centers. The big health industry business is mainly engaged in the development, research, production and sales of big health products featuring Miao medicine. The Company mainly operates its businesses in the domestic market.

Employees

4,832

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
23/06/26	CN¥3.270	+4.81%	33,286,500
22/06/26	CN¥3.120	+0.32%	20,616,923
18/06/26	CN¥3.110	-1.27%	18,397,100
17/06/26	CN¥3.150	-2.78%	15,560,420
16/06/26	CN¥3.240	-1.52%	13,848,930

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Shanghai S.E. Other stock markets 23/06/2026			5-day change	1st Jan Change
3.270 ^CNY	+4.81%		-0.61%	-17.84%

1 day	+4.81%
1 week	-0.61%
Current month	-7.63%
1 month	-12.10%
3 months	-11.14%
6 months	-23.06%
Current year	-17.84%

1 week	2.96	3.38
1 month	2.96	3.77
Current year	2.96	5.27
1 year	2.96	5.27
3 years	2.76	6.15
5 years	2.76	8.8
10 years	2.76	20.3

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUIZHOU YIBAI PHARMACEUTICAL CO., LTD.	+4.81%	-0.61%	-13.26%	-36.26%	361M
ELI LILLY AND COMPANY	+0.14%	-1.96%	+42.81%	+139.85%	983B
JOHNSON & JOHNSON	+2.24%	+0.25%	+55.80%	+42.47%	557B
ABBVIE INC.	+2.00%	+5.21%	+27.37%	+72.20%	406B
ROCHE HOLDING AG	+1.53%	-1.93%	+23.33%	+16.35%	314B
ASTRAZENECA PLC	+2.26%	+2.30%	+30.42%	+18.98%	273B
NOVARTIS AG	+2.61%	+3.11%	+29.81%	+36.09%	272B
NOVO NORDISK A/S	+2.60%	+9.79%	-31.71%	-43.45%	203B
AMGEN INC.	+0.84%	-0.12%	+27.53%	+52.98%	186B
GILEAD SCIENCES, INC.	+0.49%	-1.40%	+18.13%	+61.93%	155B
Average	+2.04%	-0.74%	+21.02%	+36.11%	335.07B
Weighted average by Cap.	+1.49%	-2.22%	+32.68%	+66.01%

	2024	2025
Net sales	2.17B 320M 281M 259M 243M 455M 30.34B 462M 3.11B 1.2B 14.88B 1.2B 1.18B 51.73B	1.86B 274M 241M 222M 208M 390M 25.99B 396M 2.67B 1.03B 12.75B 1.03B 1.01B 44.33B
Net income	-317M -46.73M -41.05M -37.82M -35.41M -66.34M -4.43B -67.46M -454M -176M -2.17B -175M -172M -7.55B	-330M -48.55M -42.65M -39.3M -36.79M -68.92M -4.6B -70.08M -472M -183M -2.26B -182M -178M -7.84B
Net Debt	411M 60.52M 53.17M 48.99M 45.86M 85.93M 5.73B 87.38M 588M 228M 2.81B 227M 222M 9.78B	217M 31.98M 28.1M 25.89M 24.23M 45.41M 3.03B 46.17M 311M 120M 1.49B 120M 117M 5.17B

Guizhou Yibai Pharmaceutical Co., Ltd. Stock

Stocks

600594

CNE000001H03

Pharmaceuticals

Valuation: Guizhou Yibai Pharmaceutical Co., Ltd.

Chart: Guizhou Yibai Pharmaceutical Co., Ltd.

Latest news : Guizhou Yibai Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Guizhou Yibai Pharmaceutical Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates